Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
0.7420
Dollar change
-0.0180
Percentage change
-2.37
%
Index- P/E- EPS (ttm)-0.23 Insider Own- Shs Outstand22.87M Perf Week-9.52%
Market Cap16.97M Forward P/E- EPS next Y- Insider Trans- Shs Float22.85M Perf Month12.42%
Income-5.28M PEG- EPS next Q- Inst Own1.20% Short Float0.09% Perf Quarter-25.80%
Sales2.25M P/S7.54 EPS this Y- Inst Trans-2.65% Short Ratio0.72 Perf Half Y30.16%
Book/sh0.23 P/B3.25 EPS next Y- ROA-91.68% Short Interest0.02M Perf Year131.44%
Cash/sh0.40 P/C1.84 EPS next 5Y- ROE-228.89% 52W Range0.25 - 2.90 Perf YTD0.27%
Dividend Est.- P/FCF- EPS past 5Y- ROI-101.03% 52W High-74.41% Beta0.18
Dividend TTM- Quick Ratio- Sales past 5Y49.58% Gross Margin8.43% 52W Low196.21% ATR (14)0.13
Dividend Ex-DateAug 01, 2018 Current Ratio- EPS Y/Y TTM25.33% Oper. Margin-711.67% RSI (14)38.67 Volatility7.38% 18.68%
Employees12 Debt/Eq0.07 Sales Y/Y TTM-87.44% Profit Margin-234.88% Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q40.33% Payout- Rel Volume0.19 Prev Close0.76
Sales Surprise-7.88% EPS Surprise350.00% Sales Q/Q25.47% Earnings- Avg Volume27.37K Price0.74
SMA20-22.86% SMA50-18.55% SMA200-33.75% Trades Volume5,228 Change-2.37%
Akso Health Group operates a social e-commerce platform principally in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of products. It also plans to develop a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The firm plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy, personalized consultation, conventional treatment planning, and other cancer related treatment services. The company was founded by Xiaobo An in March 2014 and is headquartered in Beijing, China.